BidaskClub upgraded shares of Clovis Oncology (NASDAQ:CLVS) from a strong sell rating to a sell rating in a report published on Tuesday morning.
Other equities analysts have also issued reports about the stock. SunTrust Banks dropped their price target on shares of Clovis Oncology from $95.00 to $85.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Stifel Nicolaus dropped their price target on shares of Clovis Oncology from $125.00 to $110.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Barclays set a $85.00 price target on shares of Clovis Oncology and gave the stock a buy rating in a research report on Tuesday, February 27th. Credit Suisse Group set a $86.00 price target on shares of Clovis Oncology and gave the stock a buy rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. reiterated a buy rating on shares of Clovis Oncology in a research report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company. Clovis Oncology has an average rating of Buy and a consensus target price of $87.84.
Clovis Oncology (NASDAQ CLVS) opened at $62.12 on Tuesday. The firm has a market cap of $3,040.00, a P/E ratio of -14.65 and a beta of 1.10. Clovis Oncology has a 12-month low of $45.42 and a 12-month high of $99.45. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35.
In related news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00. Following the sale, the director now owns 16,618 shares of the company’s stock, valued at $997,080. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $54.09, for a total transaction of $162,270.00. Following the sale, the insider now directly owns 180,571 shares in the company, valued at approximately $9,767,085.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,500 shares of company stock valued at $1,371,210. 12.50% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB purchased a new stake in Clovis Oncology during the fourth quarter valued at $328,000. Delek Group Ltd. purchased a new stake in Clovis Oncology during the fourth quarter valued at $2,852,000. MetLife Investment Advisors LLC purchased a new stake in Clovis Oncology during the fourth quarter valued at $1,374,000. Endurant Capital Management LP raised its stake in Clovis Oncology by 19.2% during the fourth quarter. Endurant Capital Management LP now owns 67,650 shares of the biopharmaceutical company’s stock valued at $4,600,000 after purchasing an additional 10,900 shares in the last quarter. Finally, Palo Alto Investors LLC raised its stake in Clovis Oncology by 2.2% during the fourth quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock valued at $231,389,000 after purchasing an additional 73,200 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: “Clovis Oncology (CLVS) Stock Rating Upgraded by BidaskClub” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/03/10/clovis-oncology-clvs-stock-rating-upgraded-by-bidaskclub.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.